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a Multi-component Prime-Boost 
Vaccination regimen with a 
consensus MOMP antigen enhances 
Chlamydia trachomatis clearance
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Adam A. Walters1† , Alexandra Nunes3 , João Paulo Gomes3 , Frank Follmann4 ,  
John S. Tregoning1 and Robin J. Shattock1*
1 Mucosal Infection and Immunity Group, Imperial College London, London, UK, 2 Los Alamos National Laboratory, 
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Copenhagen, Denmark
Background: A vaccine for Chlamydia trachomatis is of urgent medical need. We 
explored bioinformatic approaches to generate an immunogen against C. trachomatis 
that would induce cross-serovar T-cell responses as (i) CD4+ T cells have been shown 
in animal models and human studies to be important in chlamydial protection and (ii) 
antibody responses may be restrictive and serovar specific.
Methods: A consensus antigen based on over 1,500 major outer membrane protein 
(MOMP) sequences provided high epitope coverage against the most prevalent C. 
trachomatis strains in  silico. Having designed the T-cell immunogen, we assessed it 
for immunogenicity in prime-boost regimens. This consensus MOMP transgene was 
delivered using plasmid DNA, Human Adenovirus 5 (HuAd5) or modified vaccinia Ankara 
(MVA) vectors with or without MF59® adjuvanted recombinant MOMP protein.
results: Different regimens induced distinct immune profiles. The DNA-HuAd5-MVA-
Protein vaccine regimen induced a cellular response with a Th1-biased serum antibody 
response, alongside high serum and vaginal MOMP-specific antibodies. This regimen 
significantly enhanced clearance against intravaginal C. trachomatis serovar D infection 
in both BALB/c and B6C3F1 mouse strains. This enhanced clearance was shown to be 
CD4+ T-cell dependent. Future studies will need to confirm the specificity and precise 
mechanisms of protection.
conclusion: A C. trachomatis vaccine needs to induce a robust cellular response with 
broad cross-serovar coverage and a heterologous prime-boost regimen may be an 
approach to achieve this.
Keywords: Chlamydia trachomatis, consensus, mosaic, prime-boost regimens, adenovirus-vector vaccines, 
MVa-vector vaccines, Dna vaccines
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inTrODUcTiOn
Genital chlamydial infection is the most common cause of bacte-
rial sexually transmitted diseases (STDs) worldwide, accounting 
for more than 90 million cases of STDs globally each year (1). 
Over US$3 billion is spent annually on an estimated four million 
reported clinical cases of genital chlamydial infections in the 
US alone (2), thus development of a vaccine against Chlamydia 
trachomatis represents a significant public health priority. 
A promising vaccine antigen of C. trachomatis is the major outer 
membrane protein (MOMP). The MOMP antigen has been used 
in a range of previous pre-clinical vaccine studies with a mixture 
of encouraging (3, 4) and disappointing results (5, 6). This may 
reflect the high level of amino acid variability in the MOMP 
antigen, the basis for C. trachomatis serotypes (7).
New bioinformatic approaches have been developed to account 
for amino acid diversity and aid in the design of immunogens to 
induce cross-serovar T-cell responses: these include the design of 
mosaic or conserved antigen sequences. Mosaic vaccine antigens 
are designed with the intent to be used in polyvalent combina-
tions to optimize the coverage of potential T-cell epitopes (8), for 
example, HIV mosaic antigens increased the breadth and potency 
of vaccine-elicited immune responses (9), conferring protective 
responses in non-human primate models (10). Consensus vac-
cine antigens rely on a single centralized antigen designed to 
reduce sequence distances between the vaccine and circulating 
strains by using the most common amino acid at each position of 
the protein (11). By reducing the genetic differences between the 
vaccine and the primary isolate, consensus antigens can increase 
the breadth of immune response (12).
Here, we computationally design and in  silico assess both 
consensus and mosaic MOMP antigens for broad T-cell coverage 
against the C. trachomatis genital serovars D–K, for the reasons 
that (a) chlamydial infections in both animal models and humans 
suggest a strong protective role for CD4+ Th1-biased immune 
responses (4, 13, 14) and (b) that these may be supplemented by 
MOMP-specific antibodies able to mediate antibody-dependent 
cellular cytotoxicity (ADCC) (15).
We assess the quantity and quality of the antibody and cellular 
response to MOMP following different prime-boost combinations 
using DNA vaccines, recombinant viral vectors, and protein-in-
adjuvant formulations (16). Both DNA and recombinant viral 
vectors preferentially induce cellular immunity (17) and subunit 
proteins humoral immunity: the use of different prime-boost 
combinations can be tailored to influence the phenotype of both 
arms of induced adaptive immunity. DNA vaccine vectors, human 
Adenovirus 5 (HuAd5), and modified vaccinia Ankara (MVA) viral 
vectors have already entered phase I clinical trials, showing safety 
and tolerability (18, 19). Research groups have reported enhanced 
T-cell induction through heterologous prime-boost vaccination 
strategies in a range of disease models [including tuberculosis 
(20), HIV (21), HPV (22), and Ebola (23)] but these strategies 
have yet to be comprehensibly investigated for C. trachomatis.
We demonstrate that different vaccination regimens when used 
to deliver the same MOMP antigen via differing platforms can 
be configured to induce distinct immune outcomes. We further 
investigate which distinct MOMP-specific immune responses are 
required for enhanced C. trachomatis clearance following genital 
challenge in mice. We observe that a regimen using DNA-HuAd5-
MVA-Protein (DAMP) vaccines reduced bacterial load early after 
infection regardless of mouse strain used, and that this enhanced 
clearance while dependent upon CD4+ T-cell responses may have 
been augmented by induced MOMP-specific antibody responses.
MaTerials anD MeThODs
Bioinformatic antigen Design
One thousand four hundred sixty-four serovar E ompA sequences, 
surveyed from a total of 5,026 C. trachomatis strains isolated in 33 
distinct geographic regions from five continents were compared 
(24). Phylogenetic analysis was based on the protein sequence 
alignment derived from Ref. (24), and the maximum likelihood 
tree was created using FastTree (25) using default settings; the 
figure was generated using Rainbow Tree (www.hiv.lanl.gov). 
Forty-nine distinct ompA variants were present within the 
serovar E sequences, and were used in the in silico generation of 
the consensus MOMP (Con E) antigen sequence for the experi-
mental studies. The generated consensus and mosaic antigens 
were assessed for their coverage against different Chlamydia 
MOMP variants using the Epitope Coverage Assessment Tool 
EPICOVER. Full bioinformatic tool settings, a detailed descrip-
tion of the method, and consensus and mosaic antigen sequence 
information is provided in the File S1 in Supplementary Material.
Plasmid, Viral Vectors, and recombinant 
Protein
Mammalian codon optimized MOMP Con E antigen was syn-
thesized by GeneArt (Invitrogen, UK) and cloned into pcDNA3.1 
(Invitrogen, UK). Con E was homologously recombined into the 
E1 and E3 deleted HuAd5 genome plasmid, pAL1112 (kindly 
provided by Prof. Gavin Wilkinson, Cardiff University). Con E 
was recombined into the MVA pox vector by the Viral Vector Core 
Facility, The Jenner Institute (University of Oxford, UK). Escherichia 
coli codon optimized Con E expressed at too low a yield in BL21 
E. coli, and as such a recombinant MOMP matching C. trachomatis 
from serovar D/UW/Cx expressed in BL21 E. coli was used.
Chlamydia
Chlamydia trachomatis serovar D (strain UW-3/Cx) was provided 
by Dr. Frank Follmann (Statens Serum Institut) and propagated 
in McCoy cells as described previously (26). Chlamydial EBs 
were harvested, purified, and quantified as described in Ref. 
(26), and stored at −80°C in SPG buffer (Sucrose/Phosphate/
Glutamic acid: 0.2  M sucrose, 20  mM sodium phosphate, and 
5 mM glutamic acid).
Mice immunizations and infections
Female 6–8 weeks old BALB/c mice (Harlan, Stornoway, UK) and 
female 6–8 weeks old B6C3F1 mice (Charles River, Italy) were kept 
in specific-pathogen-free conditions in accordance with the UK 
Home Office guidelines. All work was approved by the Imperial 
College Ethical Review Process (ERP) Committee. Mice received 
immunizations at 3-week intervals (Table 1). DNA vaccinations 
were at 10  μg doses, intramuscularly into the hind quadriceps 
TaBle 1 | Multi-component prime-boost vaccine regimens.
regimen d0 d21 d42 d63 d84
DDDAM DNA DNA DNA HuAd5 MVA
DDDA DNA DNA DNA HuAd5
DDDM DNA DNA DNA MVA
DDD DNA DNA DNA
AM HuAd5 MVA
DAMP DNA HuAd5 MVA Protein
AMPP HuAd5 MVA Protein Protein
DDPP DNA DNA Protein Protein
APP HuAd5 Protein Protein
PPP Protein Protein Protein
PP Protein Protein
In vaccine regimen nomenclature, D represents DNA (+ electroporation), A represents 
HuAd5, M represents MVA, and P represents recombinant MOMP protein adjuvanted 
with MF59®.
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muscle in a volume of 50 μl with electroporation. Electroporation 
was with 5 mm electrodes at the immunization site using an ECM 
830 Square Wave Electroporation System (BTX), with three pulses 
of 100 V each, followed by three pulses of the opposite polarity 
with each pulse (PON) lasting 50 ms and an interpulse (POFF) inter-
val of 50 ms. All HuAd5 and MVA vaccinations were at dosages of 
107 PFU and 106 PFU, respectively. rMOMP was administered at a 
dose of 10 μg in a 1:1 mixture with MF59® (an oil-in-water emul-
sion adjuvant) (Novartis, Sienna, Italy) in a final volume of 50 μl 
for intramuscular immunizations. Due the multiple components 
within the immunization regimens, vehicle and vector-alone con-
trols were not included to reflect reduce, replace and refinement 
practice. Seven days prior to intravaginal infection, mice were 
injected subcutaneously with 2  mg of DMPA (Depo-Provera, 
Pfizer). For intravaginal infections, purified C. trachomatis D/
UW-3/Cx EBs were dissolved in SPG buffer to a concentration of 
4 × 107 IFU/ml, mice were anesthetized, and 10 μl of the EB solu-
tion pipetted into the mouse vagina. The optimal infective dose 
of 4 × 105 IFU of C. trachomatis D/UW-3/Cx EBs per mouse was 
previously determined by Dr. Frank Follmann, SSI (unpublished 
data) and consistent with Ref. (27, 28). Furthermore, bacterial clear-
ance profiles were consistent between naive BALB/c and B6C3F1 
mice at this infective dose (Figure S2 in Supplementary Material). 
Unfortunately C. trachomatis E/Bour could not be propagated to a 
high enough infectious titer for intravaginal infection.
intravaginal C. trachomatis load 
Quantification
Vaginal swabs were obtained at 3, 7, 10, and 14 days after infection. 
Swabs were vortexed with glass-beads in 500 μl SPG buffer and 
stored at −80°C until analysis. Infectious load was determined 
as described in Ref. (29). Inclusions were visualized by staining 
with polyclonal rabbit anti-MOMP serum (provided by Dr. Frank 
Follmann, SSI), followed by an Alexa 594-conjugated goat anti-
rabbit H + L (Life Technologies, UK).
Mice sampling
Tail bleeds were collected before regimen, and 2 weeks post each 
immunization. Blood was collected and centrifuged at 1,000 × g 
for 10 min. The serum was harvested and stored at −20°C. To 
assess IFN-γ T-cell responses, lymphocyte cultures from spleens 
were prepared as described previously (16). Vaginal lavage was 
performed at the same time points as tail bleeds, using three 25 μl 
washes/mouse with sterile phosphate buffered saline (PBS) that 
were later pooled. Lavage samples were incubated with protease 
inhibitor (Roche Diagnostics, Germany) before centrifuging at 
1,000× g for 10 min. The fluid supernatant from these samples 
was harvested and stored at −20°C.
semi-Quantitative MOMP-specific elisa, 
avidity assay, and MOMP-specific iFn-γ 
elispot
A semi-quantitative immunoglobulin ELISA protocol described 
previously (30) was followed. The avidity indices of serum 
samples were determined by their antibody–antigen binding 
resistance to 8 M urea. Serum samples were pre-diluted to give an 
OD450 nm readout between 1.0 and 1.5 in an ELISA and were added 
to MOMP antigen coated plates. Plates were then washed three 
times with either PBS-T or 8 M urea in PBS-T, before incubating 
with anti-mouse IgG-HRP. Samples were developed with TMB 
as described above. The avidity index was calculated as the per-
centage of urea treated OD450 nm/PBS-T OD450 nm. IFN-γ ELISpot 
assays (Mabtech, UK) were carried out on mouse splenocytes as 
to manufacturer’s instructions.
Depletion of cD4+ T cells
Mice were depleted of CD4+ T cells by the i.p. route with injec-
tions of 500  μg monoclonal anti-mouse CD4 IgG2b (clone 
GK1.5) (BioXcell, Cat: BE0003-1) on days −1 and +1 with respect 
to day of challenge being day 0. The depletion of CD4+ T cells 
was verified by FACS analysis on murine PBMC, splenocytes, and 
vaginal tissue on day +2 using anti-CD3e PE, anti-CD4 APC, and 
anti-CD8a eFluor605NC antibodies (All BD Biosciences, UK).
statistical analysis
All statistical analyses were carried out using Prism 6.0 (GraphPad, 
CA, USA). Normality of the data distribution was assessed using 
the Kolmogorov–Smirnov normality test. For non-parametric 
data, the Kruskal–Wallis test with Dunn’s multiple comparison 
post-test was used to compare more than two groups, or the two-
tailed Mann–Whitney test to compare two groups. For paramet-
ric data, a one-way ANOVA was used for multiple comparisons, 
with Bonferroni’s multiple comparison post-test for comparison 
of specific groups. P < 0.05 was considered significant (*p < 0.05, 
**p < 0.01, and ***p < 0.001).
resUlTs
Design and cross-serovar coverage 
assessment of consensus and Mosaic 
MOMP antigens
The worldwide prevalence of specific urogenital C. trachomatis 
serovars has not been fully characterized. A literature review 
(PubMed) identified 13 publications describing the country or 
regional serovar-specific prevalence (31–43). In 10 out of the 
13 C. trachomatis serovar surveys published, serovar E emerged 
as the most prevalent (Figure  1A). MOMP is a lead vaccine 
FigUre 1 | global C. trachomatis serovar prevalence, phylogeny, and theoretical epitope coverage of consensus and mosaic MOMP antigens.  
(a) The serovar prevalence of C. trachomatis worldwide compiled from a literature review and represented in descending prevalence at global locations.  
(B) A phylogenetic maximum likelihood tree based on the ompA sequence alignments derived from Ref. (24) was created using FastTree and the graphic generated 
by Rainbow Tree. (c) Potential epitope coverage against all serovars (total) and individual serovars (serovars D–K) were analyzed for a monovalent Con E antigen, 
Con E and Con F antigens, two mosaic antigens, a Con E antigen and a mosaic antigen, three mosaic antigens, and a Con E antigen with two additional mosaic 
antigens using EPICOVER. Mean 9-mer coverage presented against individual and total combined serovars D–K, with exact (red), off-by-1 (orange), and off-by-2 
(yellow) epitope matching.
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antigen candidate for C. trachomatis, and with worldwide MOMP 
sequence data available (24) for the differing genital serovars 
(D–K, Da, Ia, and Ja) it was possible to bioinformatically per-
form MOMP-based immunogen design. We found sequences 
within all serovars to be conserved, with only sporadic amino 
acid substitutions (Figure 1B). From our phylogenetic analyses, 
C. trachomatis has quite distant species, but high levels of con-
servation within a serovar. Thus, this kind of phylogenetic profile 
lends itself more toward a consensus antigen design approach 
as opposed to a single mosaic antigen design (8). Based on 49 
published serovar E sequence variants (24), we generated a novel 
MOMP consensus sequence (Con E), which fully matched the 
solution for a single mosaic and was identical to the circulating 
C. trachomatis strain E-Bour, as well as to eight additional partial 
MOMP protein sequences from a wide variant of geographic ori-
gins (24). Using a single consensus antigen, the potential epitope 
5Badamchi-Zadeh et al. Prime-Boost Regimens against C. trachomatis
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coverage of the E serovar led to extremely high coverage (~95%) 
(Figure 1C). For even broader coverage, our analyses suggest that 
multiple mosaic antigens may be more appropriate (Figure 1C; 
File S1 in Supplementary Material).
Differences in humoral and cellular 
immunogenicity of C. trachomatis MOMP 
Vaccines Following intramuscular Multi-
component Prime-Boost regimen screen
The immunogenicity of the consensus MOMP antigen was 
assessed in BALB/c mice immunized in multi-component prime-
boost regimens with DNA (D), HuAd5 (A), MVA (M), and protein 
with the oil-in-water emulsion adjuvant MF59® (P) vaccines 
(Table 1). The MF59® adjuvant has been demonstrated to induce 
IL-5 and IL-10 responses to the MOMP antigen and was, therefore, 
used as a comparator to the more Th1-skewing DNA and viral 
vector approaches (44). Serum and vaginal washes were sampled 
2  weeks after final immunization. The highest MOMP-specific 
serum IgG concentrations were observed after the PPP regimen 
(mean + SEM = 1.27 ± 0.16 mg/ml) and the lowest from the DDD 
regimen (mean + SEM = 15.4 ± 2.54 μg/ml) (Figure 2A). Protein 
(+ MF59®) immunization significantly increased MOMP-specific 
serum IgG concentrations compared to prime-boost regimen 
 without two protein boosts. MOMP-specific vaginal IgG concentra-
tions were measured following the multi-component prime-boost 
regimens (Figure  2B). The PPP regimen induced significantly 
higher MOMP-specific vaginal IgG than DDDAM, DDDA, 
DDDM, DDD, AM, or the naive group (p ≤ 0.05). MOMP-specific 
IgA was not detectable in the sera or vaginal washes following any 
of the prime-boost regimens (data not shown).
Viral vector vaccines have been shown to induce high and 
long-lasting cytophilic, Th1 skewed, antibody responses (45). A 
correlate for Th1 and Th2 skewing of the immune response in 
mice is the antigen-specific IgG2a to IgG1 ratio. MOMP-specific 
serum IgG2a and IgG1 concentrations were measured by ELISA, 
and their ratios calculated (Figure  2C). The highest MOMP-
specific serum IgG2a:IgG1 ratio was induced following the 
DAMP regimen (mean = 14.2), with the lowest ratio induced fol-
lowing PP (+ MF59®) vaccination (mean = 0.0036). There was a 
significant statistical difference in the IgG2a:IgG1 ratios between 
DAMP and PPP (p ≤ 0.005) and DAMP and PP (p ≤ 0.0005, one-
way ANOVA with Bonferroni’s multiple comparison post-test). 
Protein-only vaccine regimens induced Th2-biased immune 
environments indicated by IgG2a:IgG1 ratios of <1 caused by 
high IgG1 concentrations. Vaccine regimens with a vector-based 
vaccine prime consistently induced a Th1-biased, cytophilic 
antibody response as indicated by IgG2a:IgG1 ratios of >1.
To differentiate and qualitatively evaluate the humoral 
responses, an avidity assay was performed (Figure  2D). All 
protein-free regimens had mean avidity indices of <30%, with the 
DAMP and PP regimens also having low mean avidity indices. 
Regimens involving two protein boosts all had avidity indices 
>40%, with the APP regimen inducing MOMP-specific serum 
IgGs with the highest avidity (mean = 51.8%).
T-cell responses were assessed 1 week after the final immu-
nization. MOMP-specific IFN-γ + T-cell responses as assessed 
by ELISpot were induced by all prime-boost regimens, with the 
DDD and AM regimens inducing the strongest T-cell responses 
(a median of 504 and 502 SFU/106 splenocytes, respectively, 
Figure 2E). T-cell responses induced by the DDD and AM regi-
mens were significantly higher than those induced in the PP regi-
men (p ≤ 0.05). From this, we conclude that there were significant 
differences in both the quantity and quality of the antibody and 
cellular response following the different regimens.
Multi-component Prime-Boost regimens 
induce analogous immunogenicity 
Profiles in Both BalB/c and B6c3F1 Mice
As we wished to test the effect of altering the immune response on 
Chlamydial protection, the following groups were chosen for fur-
ther investigation as they gave distinct, skewed immune responses 
in the BALB/c screen: AM and DDD (T cell, low antibody), PPP 
(Th2-skewed antibody, no Th1 T cells), and DAMP (Th1-skewed 
antibody and T cell). These vaccine regimens induced compa-
rable responses in B6C3F1 mice as they did in BALB/c mice for 
MOMP-specific serum IgG concentrations (Figure 3A), MOMP-
specific vaginal IgG concentrations (Figure 3B), MOMP-specific 
serum IgG2a to IgG1 ratios (Figure  3C), and MOMP-specific 
IFN-γ T-cell responses (Figure 3D).
The DaMP Vaccine regimen enhances the 
clearance of C. trachomatis, regardless 
of Mouse strain, and is cD4+ T Dependent
Immunized BALB/c mice were challenged with C. trachomatis 
D/UW-3/Cx intravaginally. The DAMP regimen significantly 
reduced chlamydial IFU per swab at day 3 after challenge 
(median =  354 IFU/swab) compared to unvaccinated controls 
(median =  22,688 IFU/swab) (DAMP: *p =  0.0359, two-tailed 
Mann–Whitney test) (Figure 4A). There were no statistical dif-
ferences at the later sampling points of 7, 10, and 14 days (data 
not shown) after challenge reflecting the natural clearance of 
C. trachomatis in mice. The DDD, AM, and PPP regimens did 
not significantly reduce chlamydial shedding at any time points 
sampled after challenge in BALB/c mice.
Immunized B6C3F1 mice were challenged with C. trachomatis 
D/UW-3/Cx intravaginally. Similar to BALB/c mice, the DAMP 
vaccination regimen significantly reduced chlamydial IFU per swab 
at day 3 after challenge (median = 6,531 IFU/swab) compared to 
unvaccinated controls (median = 34,788 IFU/swab) (*p = 0.0303, 
two-tailed Mann–Whitney test) in B6C3F1s (Figure  4B). In 
addition, the PPP regimen significantly reduced chlamydial IFU 
per swab at day 3 after challenge (median =  8,095 IFU/swab) 
compared to unvaccinated controls (median = 34,788 IFU/swab) 
(*p = 0.0451, two-tailed Mann–Whitney test) (Figure 4B). There 
were no statistical differences at the later sampling points of day 7, 
day 10, or day 14 after challenge, and consistent with this challenge 
model, there was no oviduct pathology observed (hydrosalpinx) 
in challenged BALB/c or B6C3F1 mice (data not shown). Of the 
four tested prime-boost regimens, only the DAMP regimen con-
sistently enhanced the clearance of intravaginal C. trachomatis.
We assessed the mechanism of the vaccine-induced enhanced 
clearance. Monoclonal antibodies were used to deplete CD4+ 
FigUre 2 | antibody and cellular responses following multi-component prime-boost vaccination regimens.  
 (Continued)
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T cells in DAMP vaccinated and unvaccinated control B6C3F1 
mice prior to intravaginal challenge. There was no difference 
between the DAMP immunized CD4+ depleted groups and the 
naive CD4+ depleted group in chlamydial loads, indicating that 
the DAMP vaccine-induced enhanced clearance is CD4+ T-cell 
dependent (Figure 4C).
DiscUssiOn
New bioinformatic strategies have been developed as an approach 
to elicit broad immune responses against the more intractable 
antigenically variable pathogens, such as C. trachomatis. Two 
such approaches, consensus and mosaic, were used to design a 
MOMP antigen(s) to provide broad cellular cross-serovar cover-
age. We performed phylogenetic analyses revealing C. trachomatis 
MOMP to have quite distant species but high levels of amino acid 
conservation within a serovar. This phylogenetic structure lends 
itself more toward a consensus-based antigen design as opposed 
to a mosaic-based approach (8). Therefore, a single consensus 
MOMP antigen (Con E), constructed from variant sequences of 
the most common C. trachomatis serovar, was used. Nevertheless, 
combining the Con E antigen with additional mosaic antigens 
[that we have designed (Supplementary Material)] would provide 
complementary coverage to all other serovars. This would be a 
well-justified approach to theoretically achieve comprehensive 
coverage of all serovars in one vaccine, with no loss of coverage 
of the E serovar (Figure 1C), however assessing these additional 
antigens immunologically was out of the scope of this initial study.
Having designed our broad-coverage T-cell immunogen, we 
then assessed its immunogenicity using a range of prime-boost 
regimens. Few multi-component prime-boost vaccine regimens 
have been tested for the generation of immune responses against 
Chlamydia (46), with the majority focusing on homologous 
prime-boost strategies (47, 48). The use of different vectors 
within prime-boost regimen can help to avoid anti-vector 
immunity and improve vaccine-elicited immune responses. 
Previous uses of DNA vaccines expressing Chlamydia transgenes 
have not been adjuvanted by electroporation as in this study (49, 
50), and only one previous use of an adenovirus-vectored vac-
cine against Chlamydia muridarum (expressing CPAF) has been 
reported (46).
Following an initial screen of 11 prime-boost regimens, 4 
immunologically distinct regimens were assessed in both BALB/c 
and B6C3F1 mice. The AM, DDD, PPP, and DAMP regimens 
showed no mouse-strain-specific discrepancies in the humoral 
or cellular responses induced. Of these four regimens, only the 
DAMP vaccination regimen enhanced the clearance of intra-
vaginal C. trachomatis, regardless of mouse strain. This enhanced 
chlamydial clearance afforded by the DAMP vaccination regimen 
was dependent on CD4+ T cells, as shown by CD4+ T-cell deple-
tion following vaccination. Previous chlamydia vaccine studies 
in mice have also revealed a role for CD4+ T cells in their protec-
tion, including in the liposomal delivery of rMOMP (29) and the 
subcutaneous delivery of CTH1 (51).
The importance of IFN-γ in  vivo to chlamydia control has 
been demonstrated previously (52, 53). In this respect, it appears 
somewhat surprising that the DDD and AM regimens, inducing 
stronger T cell IFN-γ responses than DAMP, failed to show any 
evidence for enhanced clearance. However, a distinct character-
istic of the DAMP vaccination regimen was the co-induction of 
significantly higher levels of MOMP-specific IgG2a (with a high 
IgG2a/IgG1 ratio). This was in spite of the use of the protein-
adjuvant MF59®, which has previously been shown to skew T-cell 
responses against MOMP toward IL-5 and IL-10 (44); this may be 
explained by the order of immunizations, with the initial MOMP 
antigen exposures in the context of DNA and viral vector delivery 
skewing the response, as the protein-adjuvant boosted regimens 
resulted in a strong IgG1 bias. Chlamydial-specific IgG2a anti-
body concentrations have previously correlated with protection 
in animal studies (3). Thus, although enhanced clearance was 
dependent upon CD4 T-cell responses, these data suggest that 
induced IgG2a responses may have played a contributory role 
in the enhanced clearance of C. trachomatis infection. In this 
respect, EB opsonization by IgG isotypes is known to affect the 
uptake of chlamydia into cells (54). EB opsonization with a high 
IgG1 and low IgG2a anti-MOMP polyclonal sera has been shown 
to enhance infection of a cell line through the FcRn-mediated 
uptake of these IgG-coated EBs, suggesting a negative role for 
MOMP-specific IgG1 antibodies (55). The IgG2a isotype by 
contrast mediates effector functions, including ADCC, with 
evidence suggesting this effector function may facilitate the early 
clearance of a chlamydial infection (15); furthermore, ADCC is 
associated with enhanced antigen presentation with the potential 
to amplify CD4 T-cell responses (56). Collectively, these suggest 
that the anti-MOMP IgG isotype may have a contributory role 
in the protection observed from the DAMP regimen, though 
without a DAM comparator arm this would require further 
investigation.
We cannot rule out that the DAMP vaccination regimen 
itself is in fact lowering the establishment of infection and, thus, 
BALB/c mice (n = 8 per group) were intramuscularly immunized in various prime-boost regimens, with sera and vaginal wash collected 2 weeks after final boost. 
MOMP-specific IgG concentrations were measured in serum (a) and vaginal washes (B), expressed as the mean + SEM concentrations. (c) Serum MOMP-specific 
IgG2a and IgG1 isotype concentrations were measured by ELISA, and the mean + SEM IgG2a:IgG1 ratios plotted. The dotted line indicates the IgG2a:IgG1 ratio of 
1, demonstrating Th1-skewing above this line or Th2-skewing below it. (D) Serum antibody avidity was measured by MOMP-specific IgG ELISA with non-reducing 
(H2O) and reducing (8 M urea) washes after sample addition. Results are shown as percentage (%) change in binding (reducing OD450 /non-reducing OD450 × 100). 
IgG concentrations, avidities, and IgG2a:IgG1 ratio represented as group means and SEM. (e) Vaccinated BALB/c mice (n = 8 per group) were sacrificed 1 week 
post-final immunization and splenocytes assessed by IFN-γ ELISpot for MOMP-reactive T cells stimulated by a peptide pool consisting of 15-mers overlapping by 
11 amino acids. Data expressed as group medians (+ interquartile range) (SFU/million antigen stimulated cells). *p ≤ 0.05 (yellow), **p ≤ 0.005 (orange), 
***p ≤ 0.0005 (red), and ****p ≤ 0.0001 (dark red) by one-way ANOVA with Bonferroni’s multiple comparison post-test on logged values (a–D) and by Kruskal–Wallis 
with Dunn’s multiple comparison test (e).
FigUre 2 | continued
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FigUre 4 | The DaMP vaccine regimen enhances the clearance of 
intravaginal C. trachomatis in BalB/c and B6c3F1 mice, in a cD4+ 
T-cell-dependent manner. Six weeks after the final vaccination and 1 week 
after 2 mg/mouse subcutaneous Depo-Provera treatment, BALB/c and 
B6C3F1 mice (n = 7–10 per group) were infected intravaginally with 4 × 105 
IFU of C. trachomatis D/UW-3/Cx. The vaginal vault of mice were sampled 
using individual swabs at day 3 [(a) BALB/c; (B) B6C3F1] after challenge, 
and vaginal Chlamydial loads quantified by infection assay and 
immunoflorescent microscopy. The fold reduction in median Chlamydial load 
compared to naive BALB/c (a) and B6C3F1 (B) mice at day 3 after infection 
is also represented. (c) B6C3F1 mice (n = 8 per group) were immunized with 
the DAMP regimen or left unvaccinated and subsequently depleted of CD4+ 
T cells by i.p. injections of 500 μg/mouse of anti-mouse CD4 monoclonal 
antibody (clone GK1.5) on days −1 and +1 with respect to day of challenge 
day 0. C. trachomatis load was measured in the vaginal vault at day 3 after 
infection. Individual and median values are represented. *p ≤ 0.05, 
**p ≤ 0.01, and ***p ≤ 0.001, two-tailed Mann–Whitney U test.
FigUre 3 | Prime-boost vaccine regimens induce comparable 
immune responses in both BalB/c and B6c3F1 mouse strains. 
MOMP-specific IgG concentrations were measured in serum (a) and vaginal 
washes (B) for both BALB/c and B6C3F1 vaccinated mice (n = 8 per group), 
expressed as individual concentrations with bars representing the means.  
(c) Serum MOMP-specific IgG2a and IgG1 isotype concentrations were 
measured by ELISA for both BALB/c and B6C3F1 vaccinated mice (n = 5–8 
per group), and individual points and bars representing the means 
IgG2a:IgG1 ratios plotted. The dotted line indicates the IgG2a:IgG1 ratio of 1, 
demonstrating Th1-skewing above this line or Th2-skewing below it.  
(D) Splenocytes were assessed by IFN-γ ELISpot for MOMP-reactive T cells 
stimulated by a peptide pool consisting of 15-mers overlapping by 11 amino 
acids for both vaccinated BALB/c and B6C3F1 mice. Data expressed as 
individual values with bars representing group medians (+ interquartile range) 
(SFU/million antigen-stimulated cells).
resulting in the lower IFU observed, as our earliest sampling point 
is day 3 after challenge. Moreover, we cannot exclude the pos-
sibility that non-specific effects of the vaccine components in the 
9Badamchi-Zadeh et al. Prime-Boost Regimens against C. trachomatis
Frontiers in Immunology | www.frontiersin.org April 2016 | Volume 7 | Article 162
reFerences
1. WHO. Global Prevalence and Incidence of Selected Curable Sexually Transmitted 
Diseases: Overview and Estimates. Geneva: World Health Organisation (2001).
2. CDC. Sexually Transmitted Disease Surveillance 2010. Atlanta, GA: Centers for 
Disease Control and Prevention (2010).
3. Pal S, Theodor I, Peterson EM, De La Maza LM. Immunization with the 
Chlamydia trachomatis mouse pneumonitis major outer membrane protein 
can elicit a protective immune response against a genital challenge. Infect 
Immun (2001) 69:6240–7. doi:10.1128/IAI.69.10.6240-6247.2001 
4. Farris CM, Morrison SG, Morrison RP. CD4+ T cells and antibody are required 
for optimal major outer membrane protein vaccine-induced immunity to 
Chlamydia muridarum genital infection. Infect Immun (2010) 78:4374–83. 
doi:10.1128/IAI.00622-10 
5. Igietseme JU, Murdin A. Induction of protective immunity against Chlamydia 
trachomatis genital infection by a vaccine based on major outer membrane 
protein-lipophilic immune response-stimulating complexes. Infect Immun 
(2000) 68:6798–806. doi:10.1128/IAI.68.12.6798-6806.2000 
6. Sun G, Pal S, Weiland J, Peterson EM, De La Maza LM. Protection against 
an intranasal challenge by vaccines formulated with native and recombinant 
preparations of the Chlamydia trachomatis major outer membrane protein. 
Vaccine (2009) 27:5020–5. doi:10.1016/j.vaccine.2009.05.008 
7. Yuan Y, Zhang YX, Watkins NG, Caldwell HD. Nucleotide and deduced amino 
acid sequences for the four variable domains of the major outer membrane 
proteins of the 15 Chlamydia trachomatis serovars. Infect Immun (1989) 
57:1040–9. 
8. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, et al. 
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global 
HIV-1 variants. Nat Med (2007) 13:100–6. doi:10.1038/nm1461 
9. Barouch DH, O’Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, et al. 
Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune 
responses in rhesus monkeys. Nat Med (2010) 16:319–23. doi:10.1038/
nm.2089 
10. Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, 
et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous 
SHIV challenges in rhesus monkeys. Cell (2013) 155:531–9. doi:10.1016/j.
cell.2013.09.061 
11. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, et al. Diversity consid-
erations in HIV-1 vaccine selection. Science (2002) 296:2354–60. doi:10.1126/
science.1070441 
12. Eugene HS, Pierce-Paul BR, Cragio JK, Ross TM. Rhesus macaques 
vaccinated with consensus envelopes elicit partially protective immune 
responses against SHIV SF162p4 challenge. Virol J (2013) 10:102. 
doi:10.1186/1743-422X-10-102 
13. Su H, Caldwell HD. CD4+ T cells play a significant role in adoptive immunity 
to Chlamydia trachomatis infection of the mouse genital tract. Infect Immun 
(1995) 63:3302–8. 
14. Li W, Murthy AK, Guentzel MN, Seshu J, Forsthuber TG, Zhong G, et  al. 
Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate 
robust protective immunity against genital Chlamydia muridarum infection. 
J Immunol (2008) 180:3375–82. doi:10.4049/jimmunol.180.5.3375 
15. Moore T, Ananaba GA, Bolier J, Bowers S, Belay T, Eko FO, et al. Fc receptor 
regulation of protective immunity against Chlamydia trachomatis. Immunology 
(2002) 105:213–21. doi:10.1046/j.0019-2805.2001.01354.x 
16. McKay PF, Cope AV, Mann JF, Joseph S, Esteban M, Tatoud R, et  al. 
Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and 
B cell responses elicited by a DNA-MVA-protein vaccine regimen. PLoS One 
(2014) 9:e84707. doi:10.1371/journal.pone.0084707 
17. Tregoning JS, Kinnear E. Using plasmids as DNA vaccines for infectious dis eases. 
Microbiol Spectr (2014) 2:1–16. doi:10.1128/microbiolspec.PLAS-0028-2014 
18. Hayton E-J, Rose A, Ibrahimsa U, Del Sorbo M, Capone S, Crook A, et al. 
Safety and tolerability of conserved region vaccines vectored by plasmid 
DNA, simian adenovirus and modified vaccinia virus ankara administered 
to human immunodeficiency virus type 1-uninfected adults in a randomized, 
single-blind phase I trial. PLoS One (2014) 9:e101591. doi:10.1371/journal.
pone.0101591 
DAMP regimen may impact general T-cell function. Future work 
should assess the potential non-specific immunologic effects of 
antigen-delivery by viral vectors alongside adjuvantation during 
prime-boost vaccinations.
In this study, we undertook a bioinformatic approach to 
generate an immunogen that would induce cross-serovar 
Chlamydial T-cell responses. We have revealed a capability to 
induce an array of MOMP-specific immune responses, both 
cellular and humoral, using four differing MOMP-based vac-
cine modalities in multi-component prime-boost regimens. The 
comparison of the same antigen by different modalities gives us 
insight into the distinct immune profiles induced by these vac-
cines. Based on our focus of developing vaccine candidates to 
progress toward clinical testing, we opted to use C. trachomatis 
for our challenged studies, rather than the more conventional 
use of C. muridarum that is pathogenic in mice. Though C. tra-
chomatis is not a natural pathogen of mice, it has been argued 
that intravaginal infection with C. trachomatis mimics in many 
ways both the course and outcome of infection in most women 
as asymptomatic and self-limiting (57). In this context, the 
observed significant reduction in shedding following DAMP 
vaccination observed 3  days post infection is particularly 
encouraging given rapid natural clearance in naive animals. We 
would anticipate a greater impact on C. trachomatis clearance in 
transcervical infection models, in non-human primate models, 
and in humans, where the infection is slow to clear and/or may 
establish chronic infection and this will form the focus of our 
future studies.
aUThOr cOnTriBUTiOns
AB-Z, PM, BK, GB, and AW performed the experiments; AB-Z, 
PM, JT, and RS designed the studies; AN, JG, and FF provided 
data sources. AB-Z and JT wrote the paper.
acKnOWleDgMenTs
Thanks to GSK (Sienna) for the provision of the adjuvant MF59®, 
Dr. Frank Follmann (Statens Serum Institut) for the provision of 
C. trachomatis D/UW-3/Cx, the University of Oxford Viral Vector 
Core Facility for the construction of the MVA-MOMP virus, and 
Prof. Gavin Wilkinson (University of Cardiff) for the HuAd5 
genome plasmid pAL1112. Thanks to Dr. N. Provine and Dr. R. 
Larocca (Harvard Medical School) for manuscript comments 
and Dr. Christopher Thompson (Imperial College London) for 
helping with Chlamydia propagation.
FUnDing
AB was funded by the Wellcome Trust. RS was supported by 
the European Community’s European 7th Framework Program 
ADITEC (HEALTH-F4-2011-18 280873).
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fimmu.2016.00162
10
Badamchi-Zadeh et al. Prime-Boost Regimens against C. trachomatis
Frontiers in Immunology | www.frontiersin.org April 2016 | Volume 7 | Article 162
19. Nilsson C, Hejdeman B, Godoy-Ramirez K, Tecleab T, Scarlatti G, Bråve A, 
et  al. HIV-DNA given with or without intradermal electroporation is safe 
and highly immunogenic in healthy swedish HIV-1 DNA/MVA vaccinees: a 
phase I randomized trial. PLoS One (2015) 10:e0131748. doi:10.1371/journal.
pone.0131748 
20. McShane H, Brookes R, Gilbert SC, Hill AV. Enhanced immunogenicity of 
CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia 
virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect 
Immun (2001) 69:681–6. doi:10.1128/IAI.69.2.681-686.2001 
21. Hanke T, Blanchard TJ, Schneider J, Hannan CM, Becker M, Gilbert SC, et al. 
Enhancement of MHC class I-restricted peptide-specific T cell induction by 
a DNA prime/MVA boost vaccination regime. Vaccine (1998) 16:439–45. 
doi:10.1016/S0264-410X(97)00226-0 
22. Van Der Burg SH, Kwappenberg KM, O’Neill T, Brandt RM, Melief CJ, Hickling 
JK, et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 
L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost 
regimens. Vaccine (2001) 19:3652–60. doi:10.1016/S0264-410X(01)00086-X 
23. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a 
preventive vaccine for Ebola virus infection in primates. Nature (2000) 
408:605–9. doi:10.1038/35046108 
24. Nunes A, Nogueira PJ, Borrego MJ, Gomes JP. Adaptive evolution of the 
Chlamydia trachomatis dominant antigen reveals distinct evolutionary 
scenarios for B- and T-cell epitopes: worldwide survey. PLoS One (2010) 
5:e13171. doi:10.1371/journal.pone.0013171 
25. Price MN, Dehal PS, Arkin AP. FastTree: computing large minimum evo-
lution trees with profiles instead of a distance matrix. Mol Biol Evol (2009) 
26:1641–50. doi:10.1093/molbev/msp077 
26. Scidmore MA. Cultivation and laboratory maintenance of Chlamydia 
trachomatis. Curr Protoc Microbiol (2005) Chapter 11:Unit 11A 11. 
doi:10.1002/9780471729259.mc11a01s00 
27. O’Connell CM, Abdelrahman YM, Green E, Darville HK, Saira K, Smith 
B, et al. Toll-like receptor 2 activation by Chlamydia trachomatis is plasmid 
dependent, and plasmid-responsive chromosomal loci are coordinately 
regulated in response to glucose limitation by C. trachomatis but not by C. 
muridarum. Infect Immun (2011) 79:1044–56. doi:10.1128/IAI.01118-10 
28. Picard MD, Cohane KP, Gierahn TM, Higgins DE, Flechtner JB. High-
throughput proteomic screening identifies Chlamydia trachomatis antigens 
that are capable of eliciting T cell and antibody responses that provide pro-
tection against vaginal challenge. Vaccine (2012) 30:4387–93. doi:10.1016/j.
vaccine.2012.01.017 
29. Hansen J, Jensen KT, Follmann F, Agger EM, Theisen M, Andersen P. 
Liposome delivery of Chlamydia muridarum major outer membrane protein 
primes a Th1 response that protects against genital chlamydial infection in a 
mouse model. J Infect Dis (2008) 198:758–67. doi:10.1086/590670 
30. Badamchi-Zadeh A, McKay PF, Holland MJ, Paes W, Brzozowski A, Lacey 
C, et  al. Intramuscular immunisation with chlamydial proteins induces 
Chlamydia trachomatis specific ocular antibodies. PLoS One (2015) 
10:e0141209. doi:10.1371/journal.pone.0141209 
31. Lan J, Melgers I, Meijer CJ, Walboomers JM, Roosendaal R, Burger C, et al. 
Prevalence and serovar distribution of asymptomatic cervical Chlamydia 
trachomatis infections as determined by highly sensitive PCR. J Clin Microbiol 
(1995) 33:3194–7. 
32. Morre SA, Rozendaal L, Van Valkengoed IG, Boeke AJ, Van Voorst Vader PC, 
Schirm J, et al. Urogenital Chlamydia trachomatis serovars in men and women 
with a symptomatic or asymptomatic infection: an association with clinical 
manifestations? J Clin Microbiol (2000) 38:2292–6. 
33. Suchland RJ, Eckert LO, Hawes SE, Stamm WE. Longitudinal 
assessment of infecting serovars of Chlamydia trachomatis in Seattle 
public health clinics: 1988-1996. Sex Transm Dis (2003) 30:357–61. 
doi:10.1097/00007435-200304000-00016 
34. Yamazaki T, Hagiwara T, Kishimoto T, Sasaki N, Takahashi S, Ishihara O, et al. 
Distribution of Chlamydia trachomatis serovars among female prostitutes and 
non-prostitutes in Thailand, and non-prostitutes in Japan during the mid-90s. 
Jpn J Infect Dis (2005) 58:211–3. 
35. Gao X, Chen XS, Yin YP, Zhong MY, Shi MQ, Wei WH, et al. Distribution 
study of Chlamydia trachomatis serovars among high-risk women in China 
performed using PCR-restriction fragment length polymorphism genotyping. 
J Clin Microbiol (2007) 45:1185–9. doi:10.1128/JCM.02076-06 
36. Suarkia DL, Mgone CS, Lehmann D, Passey ME, Lupiwa T, Paniu MM, et al. 
Chlamydia trachomatis infection and distribution of serovars in the Eastern 
Highlands Province, Papua New Guinea. P N G Med J (2007) 50:134–44. 
37. Bandea CI, Debattista J, Joseph K, Igietseme J, Timms P, Black CM. Chlamydia 
trachomatis serovars among strains isolated from members of rural indige-
nous communities and urban populations in Australia. J Clin Microbiol (2008) 
46:355–6. doi:10.1128/JCM.01493-07 
38. Hafner L, Beagley K, Timms P. Chlamydia trachomatis infection: host 
immune responses and potential vaccines. Mucosal Immunol (2008) 1:116–30. 
doi:10.1038/mi.2007.19 
39. Donati M, Di Francesco A, D’Antuono A, Pignanelli S, Shurdhi A, Moroni 
A, et al. Chlamydia trachomatis serovar distribution and other concurrent 
sexually transmitted infections in heterosexual men with urethritis 
in Italy. Eur J Clin Microbiol Infect Dis (2009) 28:523–6. doi:10.1007/
s10096-008-0650-z 
40. Petrovay F, Balla E, Nemeth I, Gonczol E. Genotyping of Chlamydia tracho-
matis from the endocervical specimens of high-risk women in Hungary. J Med 
Microbiol (2009) 58:760–4. doi:10.1099/jmm.0.008607-0 
41. Smelov V, Quint KD, Pleijster J, Savelkoul PH, Shalepo K, Shipitsyna E, et al. 
Chlamydia trachomatis serovar distributions in Russian men and women: 
a comparison with Dutch serovar distributions. Drugs Today (Barc) (2009) 
45(Suppl B):33–8. 
42. Gallo Vaulet L, Entrocassi C, Corominas AI, Rodriguez Fermepin M. 
Distribution study of Chlamydia trachomatis genotypes in symptomatic 
patients in Buenos Aires, Argentina: association between genotype E and neo-
natal conjunctivitis. BMC Res Notes (2010) 3:34. doi:10.1186/1756-0500-3-34 
43. Papadogeorgakis H, Pittaras TE, Papaparaskevas J, Pitiriga V, Katsambas A, 
Tsakris A. Chlamydia trachomatis serovar distribution and Neisseria gonor-
rhoeae coinfection in male patients with urethritis in Greece. J Clin Microbiol 
(2010) 48:2231–4. doi:10.1128/JCM.00586-10 
44. Knudsen NP, Olsen A, Buonsanti C, Follmann F, Zhang Y, Coler RN, et al. 
Different human vaccine adjuvants promote distinct antigen-independent 
immunological signatures tailored to different pathogens. Sci Rep (2016) 
6:19570. doi:10.1038/srep19570 
45. Douglas AD, De Cassan SC, Dicks MD, Gilbert SC, Hill AV, Draper SJ. Tailoring 
subunit vaccine immunogenicity: maximizing antibody and T cell responses 
by using combinations of adenovirus, poxvirus and protein-adjuvant vac-
cines against Plasmodium falciparum MSP1. Vaccine (2010) 28:7167–78. 
doi:10.1016/j.vaccine.2010.08.068 
46. Brown THT, David J, Acosta-Ramirez E, Moore JM, Lee S, Zhong G, et al. 
Comparison of immune responses and protective efficacy of intranasal 
prime-boost immunization regimens using adenovirus-based and CpG/HH2 
adjuvanted-subunit vaccines against genital Chlamydia muridarum infection. 
Vaccine (2012) 30:350–60. doi:10.1016/j.vaccine.2011.10.086 
47. Pal S, Peterson EM, De La Maza LM. Vaccination with the Chlamydia tra-
chomatis major outer membrane protein can elicit an immune response as 
protective as that resulting from inoculation with live bacteria. Infect Immun 
(2005) 73:8153–60. doi:10.1128/IAI.73.12.8153-8160.2005 
48. Schautteet K, Stuyven E, Beeckman DS, Van Acker S, Carlon M, Chiers K, et al. 
Protection of pigs against Chlamydia trachomatis challenge by administration 
of a MOMP-based DNA vaccine in the vaginal mucosa. Vaccine (2011) 
29:1399–407. doi:10.1016/j.vaccine.2010.12.042 
49. Dong-Ji Z, Yang X, Shen C, Lu H, Murdin A, Brunham RC. Priming with 
Chlamydia trachomatis major outer membrane protein (MOMP) DNA 
followed by MOMP ISCOM boosting enhances protection and is associated 
with increased immunoglobulin A and Th1 cellular immune responses. Infect 
Immun (2000) 68:3074–8. doi:10.1128/IAI.68.6.3074-3078.2000 
50. Penttila T, Tammiruusu A, Liljestrom P, Sarvas M, Makela PH, Vuola JM, 
et al. DNA immunization followed by a viral vector booster in a Chlamydia 
pneumoniae mouse model. Vaccine (2004) 22:3386–94. doi:10.1016/j.
vaccine.2004.02.032 
51. Olsen AW, Theisen M, Christensen D, Follmann F, Andersen P. Protection 
against Chlamydia promoted by a subunit vaccine (CTH1) compared with a 
primary intranasal infection in a mouse genital challenge model. PLoS One 
(2010) 5:e10768. doi:10.1371/journal.pone.0010768 
52. Cotter TW, Ramsey KH, Miranpuri GS, Poulsen CE, Byrne GI. Dissemination 
of Chlamydia trachomatis chronic genital tract infection in gamma interferon 
gene knockout mice. Infect Immun (1997) 65:2145–52. 
11
Badamchi-Zadeh et al. Prime-Boost Regimens against C. trachomatis
Frontiers in Immunology | www.frontiersin.org April 2016 | Volume 7 | Article 162
53. Ito JI, Lyons JM. Role of gamma interferon in controlling murine chlamydial 
genital tract infection. Infect Immun (1999) 67:5518–21. 
54. Peterson EM, Cheng X, Motin VL, De La Maza LM. Effect of immunoglobulin 
G isotype on the infectivity of Chlamydia trachomatis in a mouse model of 
intravaginal infection. Infect Immun (1997) 65:2693–9. 
55. Armitage CW, O’Meara CP, Harvie MC, Timms P, Blumberg RS, Beagley 
KW. Divergent outcomes following transcytosis of IgG targeting intracellular 
and extracellular chlamydial antigens. Immunol Cell Biol (2014) 92:417–26. 
doi:10.1038/icb.2013.110 
56. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presen-
tation induces tumor immunity. J Clin Invest (2002) 110:71–9. doi:10.1172/
JCI0215640 
57. Lyons JM, Ito JI Jr, Pena AS, Morre SA. Differences in growth characteristics 
and elementary body associated cytotoxicity between Chlamydia trachomatis 
oculogenital serovars D and H and Chlamydia muridarum. J Clin Pathol 
(2005) 58:397–401. doi:10.1136/jcp.2004.021543 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Badamchi-Zadeh, McKay, Korber, Barinaga, Walters, Nunes, 
Gomes, Follmann, Tregoning and Shattock. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) or licensor are credited and that the original publication in this journal 
is cited, in accordance with accepted academic practice. No use, distribution or 
reproduction is permitted which does not comply with these terms.
